WO2014188226A3 - Lapatinib salts - Google Patents

Lapatinib salts Download PDF

Info

Publication number
WO2014188226A3
WO2014188226A3 PCT/HU2014/000047 HU2014000047W WO2014188226A3 WO 2014188226 A3 WO2014188226 A3 WO 2014188226A3 HU 2014000047 W HU2014000047 W HU 2014000047W WO 2014188226 A3 WO2014188226 A3 WO 2014188226A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
lapatinib
salts
naphtalene
new
Prior art date
Application number
PCT/HU2014/000047
Other languages
French (fr)
Other versions
WO2014188226A2 (en
Inventor
Ede MÁRVÁNYOS
János Levente HÉDER
Balázs VOLK
Tamás GREGOR
Mária TÓTHNÉ LAURITZ
László PALOTAI
Gyula LUKÁCS
László Pongó
Zoltán VARGA
András DANCSÓ
Original Assignee
Egis Gyógyszergyár Zrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Zrt. filed Critical Egis Gyógyszergyár Zrt.
Publication of WO2014188226A2 publication Critical patent/WO2014188226A2/en
Publication of WO2014188226A3 publication Critical patent/WO2014188226A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are new lapatinib salts and polymorphic forms thereof and processes for their preparation. More specifically disclosed are new salts of lapatinib, namely lapatinib salts formed by (1S)-(+)-camphorsulfonic acid, 2,5 dihydroxy benzoic acid, hydrogen bromide, malonic acid, naphtalene 1,5 disulfonic acid, naphtalene 2 sulfonic acid, nitric acid, citric acid and hydrochloric acid.
PCT/HU2014/000047 2013-05-24 2014-05-26 Lapatinib salts WO2014188226A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300332 2013-05-24
HU1300332A HU231012B1 (en) 2013-05-24 2013-05-24 Lapatinib salts

Publications (2)

Publication Number Publication Date
WO2014188226A2 WO2014188226A2 (en) 2014-11-27
WO2014188226A3 true WO2014188226A3 (en) 2015-05-14

Family

ID=89991152

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2014/000047 WO2014188226A2 (en) 2013-05-24 2014-05-26 Lapatinib salts

Country Status (2)

Country Link
HU (1) HU231012B1 (en)
WO (1) WO2014188226A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2603943C1 (en) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович CRYSTALLINE γ-MODIFICATION OF N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINOLINE AMINE OF BIS (4-METHYLBENZENESULFONATE) MONOHYDRATE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154469A1 (en) * 2007-06-11 2008-12-18 Smithkline Beecham (Cork) Limited Quinazoline salt compounds
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
WO2012017448A2 (en) * 2010-08-03 2012-02-09 Hetero Research Foundation Salts of lapatinib
CN102964339A (en) * 2012-11-19 2013-03-13 北京阜康仁生物制药科技有限公司 Novel pharmaceutical salt of lapatinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CZ299561B6 (en) 2000-06-30 2008-09-03 Glaxo Group Limited Quinazolinamine derivative and pharmaceutical composition
ITMI20110480A1 (en) 2011-03-25 2012-09-26 F I S Fabbrica Italiana Sint P A PROCEDURE FOR THE PREPARATION OF LAPATINIB AND ITS SALTS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154469A1 (en) * 2007-06-11 2008-12-18 Smithkline Beecham (Cork) Limited Quinazoline salt compounds
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
WO2012017448A2 (en) * 2010-08-03 2012-02-09 Hetero Research Foundation Salts of lapatinib
CN102964339A (en) * 2012-11-19 2013-03-13 北京阜康仁生物制药科技有限公司 Novel pharmaceutical salt of lapatinib

Also Published As

Publication number Publication date
HU231012B1 (en) 2019-11-28
HUP1300332A2 (en) 2014-11-28
WO2014188226A2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
UY34697A (en) METHODS TO PREPARE NUCLEOTID ANALOGS
DK2970283T3 (en) SUBSTITUTED 2-AZA-BICYCLO [2.2.1] HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL) AMIDES AS CATHEPSIN-C INHIBITORS
BR112015001101A2 (en) crystalline forms of a prolyl hydroxylase inhibitor
IL246133A0 (en) Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
CO7020928A2 (en) Method for producing 4,4-difluoro-3,4-dihydroisoquinoline derivatives
EP3017093A4 (en) Methods for forming white anodized films by forming branched pore structures
EA201390081A1 (en) DEUTERED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLOR-1-METHYL-2-OXOHINOLIN-3-CARBOXAMIDE, ITS SALT AND THEIR APPLICATION
MX361499B (en) Deuterated baricitinib.
DK2880151T3 (en) METHODS FOR THE PRODUCTION OF MESENKYMAL STEM CELLS THAT SEPARATE NEUROTROPHIC FACTORS
EA201590296A1 (en) DEUTERATED IBRUTINIB
EA201390613A1 (en) Enriched by rasagiline deuterium
PH12015500900B1 (en) A stabilized pemetrexed formulation
ZA201601937B (en) New salvianolic acid compound t,preparation method therefor and use thereof
DK2858986T3 (en) PIPERIDE INGREDIENTS AS GPR119 AGONISTS
FR3012137B1 (en) PROCESS FOR PRODUCING FLUORINATED COMPOUNDS
UA111333C2 (en) Method for producing l-arginine salt of perindropryl
BR112015029399A2 (en) single step production of a polypropylene composition
MX2015008829A (en) Deuterated momelotinib.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
EP2968147A4 (en) Acid stable liposomal compositions
BR112013031544A2 (en) topical composition.
FR2995343B1 (en) TURBINE BLADE, TURBINE, AND METHOD OF MANUFACTURE
BR112015022091A2 (en) crystallization aids for bayer aluminum hydroxide
BR112013024193A2 (en) method for producing a structure useful for the production of a thermoelectric generator, useful structure, thermoelectric generator
WO2014188226A3 (en) Lapatinib salts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14738887

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14738887

Country of ref document: EP

Kind code of ref document: A2